louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04397666: RT-PCR on Conjunctival Sample for the Detection of SARS-CoV-2 in Patients With Covid-19
Official title: RT-PCR on Conjunctival Sample for the Detection of SARS-Cov-2 in Patients With Covid-19
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: SARS-CoV Infection
Pinkeye
Lead sponsor: Versailles Hospital
Sponsor class: OTHER
First posted: 2020-05-21
Enrollment: 68
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: the purpose of the study is to study the detection of SARS-Cov-2 virus in the conjunctiva of covid-19 patients and the presence or absence of conjunctivitis in these patients


Eligibility criteria: Inclusion Criteria:

* Men and Women positive for SARS-Cov-2 on a RT-PCR test of a sample of respiratory airway
* Persons over 18 years of age
* patients of both sexes
* Member of a social security scheme
* Having signed the consent form

Exclusion Criteria:

* Minors not emancipated, persons out of state to express their consent
* Participation in intervention research on Covid-19 involving experimental treatment
* History of chronic disease conjunctiva
* Patient with one of the one of the criteria of following gravity:

  1. EN \> or =30/min,
  2. Pao2/Fio2 = or \< 300,
  3. confusion and/or disorientation,
  4. hypotension (Tas90mmhg, requiring aggressive filling),
  5. need for a invasive ventilation,
  6. septic shock

Primary outcomes:
measure: the SARS-Cov-2 positivity rate in patients with Covid-19 with or without signs of conjunctivitis
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Le Chesnay
country: France
facility: Centre Hospitalier de versailles
Study officials:
References:
Clinical trial NCT00277966: Cath Lab Performance Improvement
Official title: Cardiac Catheterization Laboratory Radiology Performance Improvement
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Congenital Disorders
Keywords: Pediatric
Cardiac Catheterization
Fluoroscopy time
Lead sponsor: Children's Healthcare of Atlanta
Sponsor class: OTHER
First posted: 2006-01-18
Enrollment: 0
Sex: ALL
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE

Brief summary: In 2004, the Cardiac Cath Lab at Children's Healthcare of Atlanta was asked to conduct a Quality Improvement Review examining radiation exposure.

Detailed description: In 2004, the Cardiac Cath Lab at Children's Healthcare of Atlanta was asked to conduct a Quality Improvement Review examining radiation exposure.

To perform radiological procedures with minimal radiation exposure and to ensure safe care during catheterization procedures, we conducted a chart review of all patients requiring fluoroscopy in the lab during the period of January - June, 2004.

• Based on our Retrospective Review, we were able to present Our New Standards to the Cardiac Cath Lab Committee at the end of June, 2004 with the following:

1. Diagnostic procedure time decreased from 45 minutes standard to 30 minutes standard.
2. Intervention and Electrophysiology procedure time reduced from 90 minutes to 45 minutes.

Eligibility criteria: Inclusion Criteria:

* Medical charts of all patients requiring fluoroscopy in the cardiac catheterization lab at Children's Healthcare of Atlanta, Egleston,during January - June, 2004.

Exclusion Criteria:

* Those who did not meet inclusion criteria.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Children's Healthcare of Atlanta
state: Georgia
Study officials:
affiliation: Children's Healthcare of Atlanta
name: Mary Stevens, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03187366: Schistosomiasis in Senegal
Official title: EID: Using Community Ecology Theory to Predict the Effects of Agricultural Expansion and Intensification on Infections of Humans: Implications for Sustainable Agriculture
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Schistosomiasis
Lead sponsor: University of Notre Dame
Sponsor class: OTHER
Collaborators: name: Biomedical Research Center EPLS
First posted: 2017-06-14
Enrollment: 1477
Sex: ALL
Minimum age (years): 5
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Schistosomiasis is a flatworm transmitted from freshwater snails to humans in the tropics. In addition to this infectious disease, tropical developing countries are faced with malnutrition. We propose to alter pesticide and compost use to reduce schistosomiasis and maintain or even improve crop production.

Detailed description: We propose two types of manipulations. Bottom-up manipulations will affect snail resources, whereas top-down manipulations will affect snail predators. For the bottom-up manipulations, we will clear schistosoma infections in school children, then remove the primary habitat for snails, the submerged macrophyte Ceratophyllum demersum (with proper unmanipulated controls), compost it, apply it to crops, and then quantify reinfection rates and crop yields. The second bottom-up manipulation will be to clear schistosoma infections in school children, apply three agrochemical treatments (status quo control, shift to lower risk herbicides, or eliminate herbicides and fertilizers), and then quantify reinfection rates and crop yields. Farmers will be compensated for any loss in yields. For the top-down manipulations, every village will receive prawns that depredate snails. We will clear schistosoma infections in school children, apply three agrochemical treatments (status quo control, shift to lower risk insecticides that don't kill prawns, or eliminate insecticides), and then quantify reinfection rates and crop yields. Farmers will be compensated for any loss in yields.

Eligibility criteria: Inclusion Criteria:

* School age children

Exclusion Criteria:

* Non-school age children

Primary outcomes:
measure: Schistosomiasis reinfection rate
timeFrame: One year
Secondary outcomes:
measure: Crop yields
timeFrame: One year
Other outcomes:
Locations:
city: Saint-Louis
country: Senegal
facility: Espoir Pour La Santé (EPLS)
Study officials:
affiliation: University of South Florida, Department of Integrative Biology
name: Jason R Rohr, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04813666: Lipoarabinomannan (LAM) in Urine for Diagnosis of Pulmonary Tuberculosis in HIV Patients
Official title: Role of Detection of Lipoarabinomannan (LAM) in Urine for Diagnosis of Pulmonary Tuberculosis in HIV Patients; Egyptian Experience
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: TB - Tuberculosis HIV
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2021-03-24
Enrollment: 214
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: DIAGNOSTIC

Brief summary: A diagnostic validity study in which urinary LAM was done in seropositive HIV patients with symptoms suggestive of TB who were included and investigated with battery of tests to reach the final diagnosis.

Detailed description: A diagnostic validity study in which urinary LAM was done in seropositive HIV patients with symptoms suggestive of TB who were included and investigated with battery of tests to reach the final diagnosis.

The study was conducted at Mansoura Fever Hospital in collaboration with the Chest Department and Clinical Pathology Department, Mansoura University, Egypt, from January 2015 to October 2016.

Ethical approval had been obtained from Medical Research Ethics Committee of Faculty of Medicine, Mansoura University (code no: MD/138). Approval from Egyptian Ministry of Health was taken (No: 1-2016/18). Patients signed their written consents after detailed explanation of the study protocol.

Eligibility criteria: Inclusion Criteria:

* The study included seropositive HIV patients with a new diagnosis of either pulmonary or extra-pulmonary TB, and also included patients who were presented by symptoms suggestive for tuberculosis, changes in chest X ray that not improved by full course of antibiotics or positive tuberculin test ≥ 5 mm.

Exclusion Criteria:

* Patients on anti-TB drugs or negative screening for sero-positive HIV patients were excluded from the study.

Primary outcomes:
measure: positive for TB
timeFrame: day 1
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00491166: Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser
Official title: A Single-Center, Investigator-Sponsored Pilot Study to Assess Safety and Biologic Activity of Bromfenac Ophthalmic Solution, 0.09%, in Subjects With Diffuse DME Refractory to Laser
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Diabetic Macular Edema
Keywords: diabetic macular edema
bromfenac ophthalmic solution
Lead sponsor: Ophthalmic Consultants of Boston
Sponsor class: OTHER
Collaborators: name: Bausch & Lomb Incorporated
First posted: 2007-06-25
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an investigator-sponsored trial (IST), an open-label pilot study, assessing the safety and biologic activity of bromfenac in subjects with diffuse DME refractory to laser.

Detailed description: Ten subjects will be enrolled in this study, which will be conducted at Ophthalmic Consultants of Boston, Boston, MA. All subjects must be diagnosed with diffuse DME that is either refractory to laser photocoagulation or in patients who have refused laser.

Consented subjects will be screened to determine eligibility. Eligibility will be determined by the Investigator, a retinal specialist. Only one eye will be chosen as the "study eye." Only the study eye will receive bromfenac drops during the study.

Eligible subjects will self-administer bromfenac two times per day (BID) for three months (treatment period). Subjects will have monthly examinations during the treatment period, followed by follow up visits at Month 4 and Month 6.

Eligibility criteria: Inclusion Criteria:

* Age \> 18 years
* Center-involved macular edema secondary to diabetes mellitus

Exclusion Criteria:

* Study eye with edema amenable to focal laser
* Treatment with laser, intraocular steroids, and anti-VEGF agents within 90 days
* Current eye infections

Primary outcomes:
measure: The mean change in visual acuity and central retinal thickness from baseline to month 3,and the incidence and severity of ocular adverse events and other adverse events.
timeFrame: Baseline to month 3
Secondary outcomes:
measure: Changes in retinal leakage as determined by fluorescein angiography
timeFrame: Baseline to month 3
Other outcomes:
Locations:
city: Boston
country: United States
facility: Ophthalmic Consultants of Boston
state: Massachusetts
Study officials:
affiliation: Ophthalmic Consultants of Boston
name: Jeffrey S Heier, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01379066: Tuberculosis Volatile Organic Compounds
Official title: Detection of Mycobacteria in Lungs and Culture Using an Ultra-fast Gas Chromatograph
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pulmonary Tuberculosis
Keywords: Mycobacterium tuberculosis
Pulmonary tuberculosis
Electronic nose
Gas chromatography
Lead sponsor: Landon Pediatric Foundation
Sponsor class: OTHER
First posted: 2011-06-23
Enrollment: 15
Sex: ALL
Minimum age (years): 1
Maximum age (years): 40
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Tuberculosis patients will be enrolled through the Tuberculosis Specialty Clinic in Oxnard, Ca.

Brief summary: The Pulmonary Colonization Test is a non-invasive breath test for markers of lower respiratory tract infection, which may predict the probability of mycobacterial organisms in the lower respiratory tract. It consists of:

* A breath collection apparatus for collection of volatile organic compounds in breath onto a sorbent trap and Tedlar bag, as well as for the collection of a separate sample of room air.
* Analysis of the volatile organic compounds in breath and room air by short acoustic wave/gas chromatography.
* Interpretation of the volatile organic compounds with a proprietary algorithm in order to predict the probability of lower respiratory tract colonization and infection.
* Analysis of the volatile organic compounds in sputum culture by short acoustic wave/gas chromatography.

This study will test the hypothesis that the investigators can identify the presence of mycobacteria in an individual by sampling the breath of patients with active tuberculosis and by sampling "head space" above culture media of sputum provided. This study will test the hypotheses:

* that the investigators can identify positive cultures for mycobacterium tuberculosis through sampling of the headspace above the cultures prior to standard laboratory culture identification
* that the investigators can identify control of tuberculosis by sampling exhaled breath


Eligibility criteria: Inclusion Criteria:

* Suspected tuberculosis infection or disease
* Positive tuberculosis skin test
* Positive sputum culture for TB
* X-rays indicated possible tuberculosis infection or disease
* ability to give breath and sputum samples at regular intervals

Exclusion Criteria:

* Heavy smoker
* History of or active pulmonary disease other than tuberculosis

Primary outcomes:
measure: Identification of tuberculosis from bacterial plates
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Oxnard
country: United States
facility: Oxnard Specialty Clinic
state: California
city: Ventura
country: United States
facility: Pediatric Diagnostic Center
state: California
Study officials:
References:
Clinical trial NCT04366466: Program to Promote Engagement in Care for the Prevention of Recidivism
Official title: Program to Promote Commitment to Care for the Prevention of Suicidal Recurrence (Health Monitoring and Case Management) Versus Usual Treatment (Health Monitoring): Randomized Controlled Interventional Study in Routine Care.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Suicide
Health Care Seeking Behavior
Case Management
Lead sponsor: Centre hospitalier de Ville-Evrard, France
Sponsor class: OTHER
First posted: 2020-04-29
Enrollment: 138
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Controlled, randomized and prospective study of a cohort of suicide victims comparing an experimental (interventional) group to a control group (usual treatment)
Primary purpose: PREVENTION

Brief summary: In France, the number of emergency visits for suicide attempts is estimated at 220,000 per year. Suicide management aims to reduce suicide risk factors in order to improve the mental health of patients and prevent recurrences.

To day, no study has compared the approaches to health surveillance and case management in a clinical trial, nor established the benefit of each on commitment to care and beyond the prevention of suicidal recurrence.


Eligibility criteria: Inclusion Criteria:

* Age ≥18.
* Male and female.
* Admission to CH St Denis for a suicide attempt.
* Referral for outpatient follow-up.
* Patient with no psychiatric follow-up or who has been out of follow-up for at least three months.
* Patient having given their written informed consent.

Exclusion Criteria:

* Patients not affiliated with social security or state medical aid.
* Patients who do not have the required faculties to be evaluated (cognitive and delusional disorders).
* Patients treated for more than 72 hours after their procedure (maximum length of stay in the UAS and/or in medical intensive care.
* Patient currently under psychiatric care.
* Patients who cannot be called back by telephone (no telephone, homeless, incarceration).
* Patients who do not master the French language.

Primary outcomes:
measure: Clinical Global Impression (CGI)
timeFrame: Day 0
measure: Suicide Intent Scale
timeFrame: Day 0
measure: Montgomery-Asberg depression rating scale
timeFrame: Day 0
Secondary outcomes:
measure: Evaluating the effectiveness of the P.E.P.S. program in preventing suicidal recidivism
timeFrame: 1 year
measure: Evaluate the level of possible generalization of the program
timeFrame: 1 year
measure: Evaluate the feasibility of the program
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
affiliation: Investigateur Principal
name: Fayçal MOUAFFAK
role: PRINCIPAL_INVESTIGATOR
References:
citation: Witt KG, Hetrick SE, Rajaram G, Hazell P, Taylor Salisbury TL, Townsend E, Hawton K. Psychosocial interventions for self-harm in adults. Cochrane Database Syst Rev. 2021 Apr 22;4(4):CD013668. doi: 10.1002/14651858.CD013668.pub2.
Clinical trial NCT06534866: "Effects of Kinesio Taping in Adjunct to Traditional Physical Therapy on Pain, Range of Motion and Gait Parameters in Patients With Plantar Fasciitis : a Randomized Controlled Trail"
Official title: "Effects of Kinesio Taping in Adjunct to Traditional Physical Therapy on Pain, Range of Motion and Gait Parameters in Patients With Plantar Fascitis : a Randomized Controlled Trail"
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Plantar Fascitis
Lead sponsor: Foundation University Islamabad
Sponsor class: OTHER
First posted: 2024-08-02
Enrollment: 56
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized control trial
Primary purpose: TREATMENT

Brief summary: THIS STUDY IS A RANDOMIZED CONTROL TRIAL AND THE PURPOSE OF THIS STUDY IS TO DETERMINE THE EFFECTS OF KINESIO TAPING ON GAIT PARAMETERS IN PATIENTS WITH PLANTAR FASCITIS

Detailed description: The purpose of this study is to determine the difference between efffects of KInesio taping combined with traditional physical versus physical therapy alone.

The individual of Age 20-40 years among both genders and are diagnosed cases of plantar fasciitis Pain levels will be assessed using the Numeric Pain Rating Scale (NPRS). ROM will be assessed through goniometry. Gait parameters will be assessed through 30 meter walk test. Participants of interest would be approached and explained about the research. Informed written consent will be taken. It is a single-blinded study and randomization will be done through coin toss method. Both groups will receive conventional intervention. Additionally, Group B will receive kinesio taping treatment. Baseline and post intervention scores would be recorded for both groups.

Eligibility criteria: Inclusion Criteria:

* Both genders
* Age 20-40 years
* Diagnosed Cases of plantar fasciitis as per diagnosis criteria established by APTA

As described by American Physical Therapy Association:

Plantar medial heel pain: most noticeable with initial steps after a period of inactivity but also worse following prolonged weight bearing

* Heel pain precipitated by a recent increase in weight-bearing activity
* Pain with palpation of the proximal insertion of the plantar fascia
* Positive windlass test
* Negative tarsal tunnel tests
* Limited active and passive talocrural joint dorsiflexion range of motion
* Abnormal Foot Posture Index score

Exclusion criteria:

* Recent steroid injections
* History of ankle or foot surgery
* Arthritis history
* Radiculopathy
* Diabetic foot

Primary outcomes:
measure: Pain Intensity
timeFrame: 2 weeks
measure: Range of Motion at ankle joint
timeFrame: 2 weeks
measure: Cadence (steps/min)
timeFrame: 2 weeks
measure: Cycle time (s)
timeFrame: 2 weeks
measure: Gait speed
timeFrame: 2 weeks
measure: Stride length(m)
timeFrame: 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: Foundation University College of Physical Therapy
state: Punjab
Study officials:
References:
Clinical trial NCT00000266: Flupenthixol Treatment in Schizophrenic Cocaine Abusers - 1
Official title: Flupenthixol Treatment in Schizophrenic Cocaine Abusers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Cocaine-Related Disorders
Keywords: cocaine dependence
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
Collaborators: name: New York State Psychiatric Institute
First posted: 1999-09-21
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and efficacy of flupenthixol for cocaine dependence in individuals with schizophrenia/schizoaffective illness.


Eligibility criteria: Please contact site for information.

Primary outcomes:
measure: Side effects
measure: Craving
measure: Drug use
measure: Psychiatric symptoms
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: New York State Psychiatric Institute
state: New York
Study officials:
affiliation: New York State Psychiatric Institute
name: Herbert Kleber, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05966766: Dosing Music for Anxiety Reduction in Parturients
Official title: Estimating the Effective Dose of Music Duration for Anxiety Reduction Prior to Cesarean Delivery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anxiety
Lead sponsor: Tufts Medical Center
Sponsor class: OTHER
First posted: 2023-08-01
Enrollment: 40
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a clinical study that aims to determine the effective dose of music listening duration that is required to reduce anxiety in patients awaiting scheduled cesarean section. It will also compare types of music to accomplish this goal, both of which have been shown effective in prior studies. Methods will involve enrolling and playing music for patients awaiting scheduled C-section, and scoring their anxiety with pre- and post-music questionnaires. Music duration for each subject will be predetermined, and analysis of response will be performed to determine the effective dose 95%, or dose at which 95% of subjects should have a positive response.


Eligibility criteria: Inclusion Criteria:

* Age 18 years or older
* Planning on scheduled cesarean section or non-emergent unscheduled cesarean section
* Able to provide informed consent
* American Society of Anaesthesiologists (ASA) physical status score of II-III

Exclusion Criteria:

* Patient refusal
* Impaired hearing
* Patient is taking at least one anxiolytic medication daily at baseline
* No anxiety (a score of 0, on a scale of 0-10, of pre-music exposure anxiety) after consent is given
* ASA IV or higher

Primary outcomes:
measure: Anxiety Score
timeFrame: 4-8 minutes
Secondary outcomes:
measure: STAI
timeFrame: 4-8 minutes
Other outcomes:
Locations:
city: Boston
country: United States
facility: Tufts Medical Center
state: Massachusetts
Study officials:
affiliation: Tufts Medical Center
name: Dan Drzymalski, MD
role: PRINCIPAL_INVESTIGATOR
References: